Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease

BACKGROUND: Patients with pre-existing autoimmune disease (AD) have been largely excluded from clinical trials of immune checkpoint inhibitors (ICI), so data on safety of ICIs among patients with pre-existing AD are relatively limited. There is a need for deeper understanding of the type and managem...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Swetha, Swami, Umang, Kaur, Aneet, Gao, Yubo, Fatima, Munazza, Ginn, Meredith M., Stein, Jill E., Grivas, Petros, Zakharia, Yousef, Singh, Namrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article on Cancer Immunotherapy: Recent Advances and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267316/
https://www.ncbi.nlm.nih.gov/pubmed/34277833
http://dx.doi.org/10.21037/atm-20-8124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267316/
https://www.ncbi.nlm.nih.gov/pubmed/34277833
http://dx.doi.org/10.21037/atm-20-8124

Ejemplares similares